To include your compound in the COVID-19 Resource Center, submit it here.

La Jolla's Giapreza lowers distributive shock mortality in Phase III

La Jolla Pharmaceutical Co. (NASDAQ:LJPC) presented data from a pre-specified analysis of the Phase III ATHOS-3 trial showing that IV Giapreza angiotensin II (formerly LJPC-501) improved the 28-day mortality rate vs. placebo in 123 patients with high severity of

Read the full 390 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers